CASTOR2

Across TCGA pan-cancer cohorts, CASTOR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CASTOR2 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CASTOR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CASTOR2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where CASTOR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.959	0.609	.006	25	view →
GBM	DFS	Quartile	All	0.577	0.241	<.001	15	view →
LSCC	OS	Quartile	All	0.905	0.617	.022	11	view →
PDAC	OS	Median	III,IV	0.874	0.659	.025	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CASTOR2–CCRCC (OS)

Open the CCRCC breakdown →